Bluebird's next gene therapy gets backing from European regulator
Dive Brief: A committee that advises Europes drug regulator is recommending that a gene therapy developed by Bluebird bio for a rare, often deadly disease be approved for market. The disease, known as adrenoleukodystrophy or ALD for short, is caused by genetic mutations that lead to a toxic buildup of molecules in the brain and spinal cord.ย In clinical testing, Bluebirds therapy, now called Skysona, has shown positive effects on cerebral ALD โย the most common and severe form of the disease ...
United Kingdom United States David Davidson European Union European Medicines Agency European Commission
Source: biopharmadive.com